Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Urothelial Carcinoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Hepatocellular Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Colorectal Cancer; Head and Neck Cancer; Differentiated Thyroid Cancer
Interventions: Drug: cabozantinib; Drug: atezolizumab
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.